Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Current Taxes (2022 - 2025)

Gyre Therapeutics (GYRE) has disclosed Current Taxes for 4 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • Quarterly Current Taxes rose 3.85% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Dec 2025, up 3.85% year-over-year, with the annual reading at $2.9 million for FY2025, 3.85% up from the prior year.
  • Current Taxes for Q4 2025 was $2.9 million at Gyre Therapeutics, up from $2.6 million in the prior quarter.
  • The five-year high for Current Taxes was $6.5 million in Q1 2024, with the low at $569000.0 in Q1 2025.
  • Average Current Taxes over 4 years is $2.9 million, with a median of $2.7 million recorded in 2024.
  • The sharpest move saw Current Taxes soared 140.55% in 2023, then tumbled 91.21% in 2025.
  • Over 4 years, Current Taxes stood at $2.1 million in 2022, then skyrocketed by 140.55% to $5.1 million in 2023, then tumbled by 43.98% to $2.8 million in 2024, then increased by 3.85% to $2.9 million in 2025.
  • According to Business Quant data, Current Taxes over the past three periods came in at $2.9 million, $2.6 million, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.